Ignite Creation Date:
2024-05-05 @ 5:01 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00375908
Status:
COMPLETED
Last Update Posted:
2015-09-01
First Post:
2006-09-11
Brief Title:
Umbilical Cord Blood Proteomic Analysis and Neonatal Brain Injury
Sponsor:
Johns Hopkins University
Organization:
Johns Hopkins University
Study Overview
Official Title:
Umbilical Cord Blood Proteomic Analysis and Neonatal Brain Injury
Status:
COMPLETED
Status Verified Date:
2015-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators propose to compare the proteomic analysis of umbilical venous blood from neonates with brain injury to gestational age matched noninjured controls After delivery an umbilical arterial gas and a 10 ml umbilical venous sample are obtained then the remainder of the cord blood is discarded The investigators plan to use this cord blood that would otherwise be discarded to perform our proteomic analysis The investigators will use up to 20 ml of cord blood per delivery This will be a 5 year study during which time the investigators hope to analyze 450 infants at Johns Hopkins Hospital and Bayview Medical Center The investigators will obtain an umbilical venous sample from infants born at 34 weeks gestation For infants born at 34 weeks the investigators will obtain an umbilical venous sample for any infant suspected to be at risk for neurologic injury by having a diagnosis of chorioamnionitis during labor nonreassuring fetal heart rate tracing at the time of delivery or a 5 minute Apgar 7 For the infants born at 34 weeks the brain injured infants will be compared to gestational age matched controls without brain injury For the infants born at 34 weeks each infant later confirmed to have neurologic morbidity will be compared to a gestational age matched noninjured control The investigators hope to use proteomic analysis to determine if there are measurable differences in protein expression between the 2 groups
Detailed Description:
We will draw up to 20 ml of umbilical venous blood at the time of delivery from infants born at 34 weeks gestation and for any infant born at 34 weeks suspected to be at risk for neurologic morbidity by having intrapartum chorioamnionitis nonreassuring fetal heart tracing prior to delivery or a 5 minute Apgar 7 For each infant born at 34 weeks later confirmed to have neurologic morbidity by head ultrasound or EEG we will draw cord blood from a gestational age matched control without intrapartum infection or nonreassuring fetal heart tracing prior to delivery At the time of delivery an umbilical arterial gas and umbilical venous sample for a type and screen RPR and hematocrit are routinely drawn The remainder of the cord blood is discarded After the routinely done arterial blood gas and umbilical venous blood sample are obtained the remainder of the umbilical cord blood which would otherwise be discarded will be collected using a 23 gauge or larger needle into a heparinized tube The sample will be centrifuged for 10 minutes and the plasma layer separated The sample will be placed into 15 ml eppendorf tubes in 500 ul aliquots Proteomic techniques including mass spectrometry 2-dimensional electrophoresis and chromatography will be used to analyze the proteome from the brain injured and control groups Specific proteins will be identified and differences in expression compared between the 2 groups
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None